Navigation Links
Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi
Date:1/17/2012

se of cancer death in the United States, in both men and women.[iii]  It is estimated that more than 140,000 people will be diagnosed with CRC in 2011, and nearly 50,000 people will die from the disease.[iv] Approximately 50 percent of colon cancer patients will be diagnosed with metastases (most commonly to the liver) either at the time of diagnosis or due to recurrent disease.[v]

About Regorafenib

Regorafenib is an investigational oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic kinases[vi] and is currently being investigated in clinical trials for its potential to treat patients with various tumor types.

Regorafenib is an investigational agent and is not approved by the FDA, EMA or other health authorities. 

Regorafenib is one of several cancer compounds in Bayer's development pipeline.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer and other serious diseases.  The company is focused on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements
This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, the expanded access program, safety, regulatory processes, commercialization efforts or commercial potential of carfilzomib. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related t
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Niiki Pharma Announces the Completion of Phase I Dose Escalation for First-in-Man Anti-Cancer Agent NKP-1339
2. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
3. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
4. Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study
5. Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI): Phase III Data on Bayers Investigational Compound Regorafenib (BAY 73-4506) in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Or
6. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
7. Circadian Commences First Phase 1 Clinical Trial of VEGF-C Antibody VGX-100 in Cancer Patients
8. Pearl Therapeutics Announces Successful Completion of Phase 2b Safety and Efficacy Studies of COPD Combination, PT003
9. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
10. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
11. ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... , May 29, 2015 Eli Lilly and ... Sachs 36th Annual Global Healthcare Conference on Tuesday, June ... and president, Elanco Animal Health, will participate in a ... A live audio webcast will be available ... website at http://investor.lilly.com/events.cfm . A replay of the ...
(Date:5/29/2015)... SPARTANBURG, South Carolina , May 29, 2015 /PRNewswire/ ... Health have announced a collaboration designed to provide therapeutic ... the majority of cancer patients living in U.S. communities. ... Molecular Health to harness the power of big data ... of thousands of patients to enable ,accrual on demand, ...
(Date:5/29/2015)... Research and Markets ( ... "Surgical/Operating Microscopes Market by Application & End ... to their offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... poised to reach $806.6 million by 2020 from ... 12.3% from 2015 to 2020. , ,Major factors ...
Breaking Medicine Technology:Lilly to Participate in Goldman Sachs Global Healthcare Conference 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2
... 12 A new software technology is helping to ... by electronically identifying the sperm, eggs, resulting embryos and ... (IVF) treatment cycles. Using non-invasive Radio Frequency Identification (RFID), ... embryos during the course of treatment. If the wrong ...
... ABBOTT PARK, Ill., Nov. 12 Nearly one in three ... and nearly 34 million have low HDL "good" cholesterol levels. ... and trigs, Abbott has launched two Web sites: ... "Unhealthy high triglyceride and low HDL levels are factors that ...
Cached Medicine Technology:New Technology Reduces Risk of IVF Laboratory Mistakes by Electronically Identifying Sperm, Eggs and Other Materials for Each Patient 2New Technology Reduces Risk of IVF Laboratory Mistakes by Electronically Identifying Sperm, Eggs and Other Materials for Each Patient 3New Web Sites Educate About Triglycerides and HDL Cholesterol 2
(Date:5/30/2015)... May 30, 2015 At 73 years old, ... vibrant health , which she attributes to a lifetime ... of good nutrition with the release of her new book ... Xlibris AU). , “Cook for Health and Longevity” features a ... and mostly organic food . It is designed to ...
(Date:5/30/2015)... 2015 Cyclist Barry Haarde will ... the World 2015: Piles of Miles” near San ... about hemophilia and encourage individuals to support needy ... Save One Life supports nearly 1,200 impoverished children ... through direct sponsorships, scholarships and micro-enterprise grants. Hemophilia ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 San ... that she is offering a free analysis and consultation ... offer coincides with Disability Awareness Month, which was created ... members across the United States such as Polk recognize ... raise awareness about the possibility of disability, as well ...
(Date:5/30/2015)... The iconic American actor, and host ... a new segment on Medical Malpractice. This segment of ... in the health care field. , According to the ... malpractice suits were filed, roughly only 20% of them ... of court, while the remaining 30% were tossed out. ...
(Date:5/30/2015)... May 30, 2015 “ Milli the Snail ... AppWatch, which takes a look at the latest and coolest ... Toohey, the host of AppWatch and technology expert, conducted the ... aesthetic game that engages and educates children. , Interactive mobile ... not all the content and games they are playing are ...
Breaking Medicine News(10 mins):Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2
... WILMINGTON, Delaware, September 2 According to a ... by MarketsandMarkets,( http://www.marketsandmarkets.com ), the global emerging lighting technologies,market ... recording an,estimated CAGR of 7.9% from 2009 to 2014. ... 39% of the total revenues. , ...
... , , SAN JOSE, Calif., Sept. ... company, today announced that its IsoFlow (TM) infusion ... Drug Administration (FDA) for the direct delivery of medications into highly ... treatment of cancer. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090902/SF69552 ) ...
... What you need to know about vaccinations for swine flu, ... fall, Americans will face a double challenge in getting shots ... and the seasonal variety. , "Two different vaccines are ... Hay, an assistant professor of medicine at the University of ...
... , , , LA JOLLA, ... today announced that Dr. Juliet Singh, President and Chief Executive Officer ... Partners Healthcare Conference in Boston, MA on Wednesday, September 9, 2009 ... can access a live audio webcast via the Internet by visiting ...
... , , WASHINGTON, Sept. 2 Danaher ... has signed a definitive agreement with MDS Inc. (TSX: MDS; ... division of MDS, which includes a 50% ownership position in ... business, and a 100% ownership position in the former Molecular ...
... , , MOUNTAIN VIEW, Calif., Sept. ... it will participate in the following events in September: , , ... Friday, September 11, at 10:20 a.m. ET in Boston, ... 13, in Philadelphia, Late-Breaking oral platform presentation on Saturday, September ...
Cached Medicine News:Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 2Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4Health News:Keep Your Flu Shots Straight This Fall 2Health News:Keep Your Flu Shots Straight This Fall 3Health News:Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: